标题
ABCB1 and ABCG2 restrict the brain penetration of a panel of novel EZH2-Inhibitors
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF CANCER
Volume 137, Issue 8, Pages 2007-2018
出版商
Wiley
发表日期
2015-04-14
DOI
10.1002/ijc.29566
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- P-Glycoprotein, CYP3A, and Plasma Carboxylesterase Determine Brain and Blood Disposition of the mTOR Inhibitor Everolimus (Afinitor) in Mice
- (2014) S. C. Tang et al. CLINICAL CANCER RESEARCH
- ABCB1, ABCG2, and PTEN Determine the Response of Glioblastoma to Temozolomide and ABT-888 Therapy
- (2014) F. Lin et al. CLINICAL CANCER RESEARCH
- Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma
- (2014) S. K. Knutson et al. MOLECULAR CANCER THERAPEUTICS
- An Orally Bioavailable Chemical Probe of the Lysine Methyltransferases EZH2 and EZH1
- (2013) Kyle D. Konze et al. ACS Chemical Biology
- Phosphorylation of EZH2 Activates STAT3 Signaling via STAT3 Methylation and Promotes Tumorigenicity of Glioblastoma Stem-like Cells
- (2013) Eunhee Kim et al. CANCER CELL
- Identification of EZH2 and EZH1 Small Molecule Inhibitors with Selective Impact on Diffuse Large B Cell Lymphoma Cell Growth
- (2013) Shivani Garapaty-Rao et al. CHEMISTRY & BIOLOGY
- Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the Blood-Brain Barrier without restriction by ABCB1 and ABCG2
- (2013) Fan Lin et al. INTERNATIONAL JOURNAL OF CANCER
- Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA
- (2013) Serena Marchetti et al. INVESTIGATIONAL NEW DRUGS
- Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2
- (2013) S. K. Knutson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors
- (2012) Mukul Minocha et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Oral Availability and Brain Penetration of the B-RAFV600E Inhibitor Vemurafenib Can Be Enhanced by the P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Inhibitor Elacridar
- (2012) Selvi Durmus et al. MOLECULAR PHARMACEUTICS
- Insight into the Cooperation of P-glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) at the Blood–Brain Barrier: A Case Study Examining Sorafenib Efflux Clearance
- (2012) Sagar Agarwal et al. MOLECULAR PHARMACEUTICS
- EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
- (2012) Michael T. McCabe et al. NATURE
- Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation
- (2012) W. Qi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The role of EZH2 in tumour progression
- (2011) C-J Chang et al. BRITISH JOURNAL OF CANCER
- Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration
- (2011) Seng Chuan Tang et al. INTERNATIONAL JOURNAL OF CANCER
- P-Glycoprotein (ABCB1) Transports the Primary Active Tamoxifen Metabolites Endoxifen and 4-Hydroxytamoxifen and Restricts Their Brain Penetration
- (2011) D. Iusuf et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- The Polycomb complex PRC2 and its mark in life
- (2011) Raphaël Margueron et al. NATURE
- PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel
- (2010) Yong Zhang et al. COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE
- Role of P-Glycoprotein and Breast Cancer Resistance Protein-1 in the Brain Penetration and Brain Pharmacodynamic Activity of the Novel Phosphatidylinositol 3-Kinase Inhibitor GDC-0941
- (2010) L. Salphati et al. DRUG METABOLISM AND DISPOSITION
- Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP
- (2010) Nienke A. de Vries et al. INVESTIGATIONAL NEW DRUGS
- Kinetic Analysis of the Cooperation of P-Glycoprotein (P-gp/Abcb1) and Breast Cancer Resistance Protein (Bcrp/Abcg2) in Limiting the Brain and Testis Penetration of Erlotinib, Flavopiridol, and Mitoxantrone
- (2010) H. Kodaira et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Deregulation of H3K27 methylation in cancer
- (2010) Eva Martinez-Garcia et al. NATURE GENETICS
- Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells
- (2010) F. Orzan et al. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY
- Epigenetic gene regulation in stem cells and correlation to cancer
- (2009) Lesley A. Mathews et al. DIFFERENTIATION
- P-glycoprotein and Breast Cancer Resistance Protein Influence Brain Distribution of Dasatinib
- (2009) Y. Chen et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Substrate-Dependent Breast Cancer Resistance Protein (Bcrp1/Abcg2)-Mediated Interactions: Consideration of Multiple Binding Sites in in Vitro Assay Design
- (2008) N. Giri et al. DRUG METABOLISM AND DISPOSITION
- Several major antiepileptic drugs are substrates for human P-glycoprotein
- (2008) Carlos Luna-Tortós et al. NEUROPHARMACOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started